Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.

Implementation challenges and the importance of equitable access in the future of multi-cancer early detection tests.

Shared insight into the efficiency of diagnostic resolution approaches, comparing imaging-based and molecular tissue of origin strategies in multi-cancer early detection testing.

Expert perspectives about the ASCEND trial, its study design, and the critical role it plays in developing advanced cancer detection methods.

Key opinion leaders review the rationale behind multi-biomarker approaches and how they're shaping the future of cancer detection and research.

Discover the potential clinical implications of groundbreaking cancer screening studies, DETECT-A and PATHFINDER, and the evolving landscape of multi-cancer early detection.

Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.

Shared insight into findings of the DETECT-A study, a prospective interventional trial, covering feasibility, safety, and performance of multicancer early detection tests in a healthcare system setting.

The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.

Expert panelists delve into multicancer early detection testing and discuss its potential to revolutionize cancer screening, close healthcare gaps, and complement standard care approaches.

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.